Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:16:31.095Z.
Consensus retrieved: 2026-10-06T11:02:08.870Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:16:31.095Z.
Quote observation: 2026-10-06T14:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5259cb07e2fbb96f0e8f0a81153900e7454c243d03e5865b91db876a0b9f3ffb
Forward PE Ratio (N/A) = Dated Quote Price ($2.80) / Consensus Forward EPS ($-0.78)
FORWARD PE RATIO
N/A
Editas Medicine, Inc.
Market Cap
$429.68M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Editas Medicine, Inc. (EDIT) | $429.68M | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $433.92M | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.65M | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $416.52M | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $411.75M | N/A |
| Carlsmed, Inc. (CARL)vs › | $410.49M | N/A |
| NeoGenomics, Inc. (NEO)vs › | $449.79M | 95.80 |
| Shoulder Innovations, Inc. (SI)vs › | $408.44M | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $451.27M | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $407.35M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.80, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.78 | $-0.96 – $-0.63 | 8 | n/m |
| 2027-12-31 | $-0.71 | $-1.02 – $-0.57 | 8 | n/m |
| 2028-12-31 | $-0.75 | $-0.87 – $-0.65 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
